2002;359:995 1003. S3.1-20. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med. 2009;122:290 300. S3.1-21. ChobanianAV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. S3.1-22. Yoon SS, Gu Q, Nwankwo T, et al. Trends in blood pressure among adults with hypertension: United States, 2003 to 2012. Hypertension. 2015;65:54 61. 3.2. Lifetime Risk of Hypertension S3.2-1. Muntner P, Woodward M, Mann DM, et al. Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis. Hypertension. 2010;55:1339 45. S3.2-2. Parikh NI, Pencina MJ, Wang TJ, et al. A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med. 2008;148:102 10. S3.2-3. Carson AP, Howard G, Burke GL, et al. Ethnic differences in hyper- tension incidence among middle-aged and older adults: the multi- ethnic study of atherosclerosis. Hypertension. 2011;57:1101 07. S3.2-4. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003 10. S3.2-5. Shihab HM, Meoni LA, Chu AY, et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation. 2012;126:2983 9. 3.3. Prevalence of High BP S3.3-1. Whelton PK. The elusiveness of population-wide high blood pres- sure control. Annu Rev Public Health. 2015;36:109 30. S3.3-2. Crim MT, Yoon SSS, Ortiz E, et al. National surveillance defini- tions for hypertension prevalence and control among adults. Circ Cardiovasc Qual Outcomes. 2012;5:343 51. S3.3-3. 